CAS: 173606-11-6

Heterocyclic compounds with nitrogen hetero-atom(s) only, aromatic or modified aromatic, nesoi

Stability Hygroscopic Applications N-Acetyl-Phe-Octreotide is used as reactant/reagent in inhibition of octreotide acylation inside PLGA microspheres by derivatization of amines of peptide with self-immolative protecting group. References Shirangi, M., et al.: Bioconjugate Chem., 27, 576-585 (2016)

Potential impurity of octreotide.

Polypeptide, protein and glycoprotein hormones, their derivatives and structural analogues, nesoi

Octreotide is a somatostatin analog that is used to treat acromegaly, carcinoid syndrome, and other conditions. Octreotide has been shown to be effective in the treatment of bowel disease and inflammatory bowel disease. The long-term efficacy of octreotide has been demonstrated with positron emission tomography (PET) studies in patients with human serum. Octreotide binds to receptors on cells that produce growth hormone and inhibits the release of somatostatin from these cells. It also inhibits the production of insulin by binding to receptors on beta cells in the pancreas. Octreotide is synthesized as Lys(ac)⁵)-octreotide acetate salth-D-Phe-Cys-Phe-D-Trp-Lys(ac)-Thr-Cys-L-threoninol acetate salt (disulfide bond). This product can be identified by a hydroxyl group on one side of